Shingleton H M, Bell M C, Fremgen A, Chmiel J S, Russell A H, Jones W B, Winchester D P, Clive R E
Emory University, Atlanta, Georgia, USA.
Cancer. 1995 Nov 15;76(10 Suppl):1948-55. doi: 10.1002/1097-0142(19951115)76:10+<1948::aid-cncr2820761311>3.0.co;2-t.
The authors' aim was to assess whether there is a difference in biologic behavior and survival in comparing adenocarcinoma (AdCA), squamous cell carcinoma (SCC), and adenosquamous carcinoma (Ad/SC) of the cervix.
Cancer registrars at 703 hospitals submitted anonymous data on 11,157 patients with cervical cancer diagnosed and/or treated in 1984 and 1990 for a Patient Care Evaluation Study of the American College of Surgeons. Among these patients, 9351 (83.8%) had SCC; 1405 (12.6%), AdCA; and 401 (3.6%), Ad/SC cancers. There were no significant changes in percentages of the different histologic types between the study years 1984 and 1990, nor was the patient distribution different regarding age, race/ethnicity, and socioeconomic background for each histologic group. Furthermore, the distribution of patients who had had a hysterectomy did not change between 1984 and 1990.
A larger percent of patients with SCC (63.8%) than those with Ad/SC (59.8%) or AdCA (50.2%) had tumors larger than 3 cm at greatest dimension. Early stage patients (IA, IB, IIA) often were treated by hysterectomy alone (45.5%) or combined with radiation (21.1%). The remaining patients (21.9%) received radiation alone. Of the patients with clinical stage I disease, 7.6% of Ad/CA patients, 15.5% of Ad/SC patients and 12.6% of SCC patients had positive nodes. Although patients with SCC had higher survival rates for all four clinical stages (I-IV), the differences were only significant for Stage II patients. Patients with clinical stage IB SCC and AdCA treated by surgery alone were found to have significantly better survival rates (93.1% and 94.6% at 5 years, respectively) than women treated by either radiation alone or a combination of surgery and radiation (P < 0.001, both histologic comparisons). For women with Ad/SC tumors, however, the 5-year survival rate was 87.3% for those receiving combined treatment compared with those receiving surgery alone (69.2%) or radiation alone (79.2%). However, these survival curves were not significantly different (P = 0.496). One hundred six patients with positive nodes were available for analysis. The 5-year survival rate of patients with SCC and positive nodes was 76.1%. Surprisingly, patients with Ad/SC and positive nodes had the highest 5-year survival rate (85.7%), whereas, women with AdCA and positive nodes had a sharply reduced 5-year survival rate (33.3%). The curves were significantly different (P < 0.01). For patients with clinical stage I, the risk factors for age, tumor size, nodal status, histologic features, and treatment were analyzed with Cox's multivariate regression. In this analysis, subset IB, greater tumor size, age 80 or older, and positive nodal status were each independently significant for poorer survival. Patients who were treated by surgery alone had a significantly better survival than patients who had other types of treatment or no treatment. Histologic characteristics had no significant effect on survival. In the analysis of patients with pathologic stage I disease, those with SCC had significantly poorer survival and those with Ad/SC had significantly better survival than patients with Ad/CA. Positive nodes had no significant independent effect on survival. In another analysis, tissue type was not found to be an important factor in recurrence time.
作者的目的是评估子宫颈腺癌(AdCA)、鳞状细胞癌(SCC)和腺鳞癌(Ad/SC)在生物学行为和生存率方面是否存在差异。
703家医院的癌症登记员提交了1984年和1990年诊断和/或治疗的11157例宫颈癌患者的匿名数据,用于美国外科医师学会的患者护理评估研究。在这些患者中,9351例(83.8%)为SCC;1405例(12.6%)为AdCA;401例(3.6%)为Ad/SC癌。在1984年和1990年的研究年份之间,不同组织学类型的百分比没有显著变化,并且每个组织学组在年龄、种族/民族和社会经济背景方面的患者分布也没有差异。此外,1984年至1990年间接受子宫切除术的患者分布没有变化。
SCC患者中肿瘤最大直径大于3cm的比例(63.8%)高于Ad/SC患者(59.8%)或AdCA患者(50.2%)。早期患者(IA、IB、IIA期)通常仅接受子宫切除术(45.5%)或联合放疗(21.1%)。其余患者(21.9%)仅接受放疗。在临床I期患者中,Ad/CA患者的7.6%、Ad/SC患者的15.5%和SCC患者的12.6%有阳性淋巴结。尽管SCC患者在所有四个临床分期(I-IV期)的生存率较高,但差异仅在II期患者中显著。发现单独接受手术治疗的临床IB期SCC和AdCA患者的生存率(5年时分别为93.1%和94.6%)明显高于单独接受放疗或手术与放疗联合治疗的女性(P<0.001,两种组织学比较均如此)。然而,对于患有Ad/SC肿瘤的女性,接受联合治疗的患者5年生存率为87.3%,而接受单独手术(69.2%)或单独放疗(79.2%)的患者生存率较低。然而,这些生存曲线没有显著差异(P = 0.496)。106例有阳性淋巴结的患者可供分析。SCC且有阳性淋巴结患者的5年生存率为76.1%。令人惊讶的是,Ad/SC且有阳性淋巴结患者的5年生存率最高(85.7%),而AdCA且有阳性淋巴结的女性5年生存率急剧下降(33.3%)。曲线有显著差异(P<0.01)。对于临床I期患者,使用Cox多变量回归分析年龄、肿瘤大小、淋巴结状态、组织学特征和治疗的危险因素。在此分析中,子集IB、更大的肿瘤大小、80岁或以上的年龄以及阳性淋巴结状态各自独立地对较差的生存有显著影响。单独接受手术治疗的患者生存率明显高于接受其他类型治疗或未接受治疗的患者。组织学特征对生存没有显著影响。在病理I期疾病患者的分析中,SCC患者的生存率明显较差,Ad/SC患者的生存率明显高于Ad/CA患者。阳性淋巴结对生存没有显著的独立影响。在另一项分析中,未发现组织类型是复发时间的重要因素。